About PrescribedReta.

What this site is

PrescribedReta is an independent editorial project that publishes plain-language summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name "PrescribedReta" is an SEO domain — a search-oriented address in the domain name itself. It does not reflect the nature of this site's content or services. Nothing here is prescribed, dispensed, or sold.

Why retatrutide

Retatrutide is the most clinically active investigational compound in the obesity and metabolic disease drug pipeline as of 2025–2026. The Phase 2 weight-loss trial results — a mean -24.2% body-weight reduction at 48 weeks in the highest-dose group — drew significant attention in metabolic medicine. The kidney and liver-fat substudies added further clinical depth. The TRIUMPH Phase 3 program and the TRANSCEND-CKD trial mean retatrutide will be generating trial data for the next several years.

This site exists to organize that research into a readable form. The Retatrutide research page covers the trial chronology. The Retatrutide effects page separates what trials measured from what the research community reports. The results page focuses on quantitative outcomes from the Phase 2 and emerging Phase 3 data.

Editorial standards

Every quantitative claim on this site is cited to a published source. We use inline numbered citations throughout and maintain a full Retatrutide references index. We do not cite preprints as settled evidence. We do not invent findings or extrapolate beyond what published studies report.

We do not write competitor brand names or link to gray-market vendors. We do not provide dosing guidance, administration instructions, or reconstitution protocols for non-trial use. We do not recommend any use of retatrutide outside of supervised clinical-trial participation.

When the published literature does not yet contain an answer — as it does not on several open Phase 3 questions — we say so plainly.

Corrections and contact

If you identify an error in citation, a factual inaccuracy, or a claim that misrepresents a source, please contact us via the contact page. We take accuracy corrections seriously and publish updates when warranted. This site is updated as new primary literature is published. The most recent significant updates reflect 2025 kidney outcomes data from Phase 2 substudies and the TRANSCEND-CKD trial design publication.